Difference between revisions of "Profiles"
Jump to navigation
Jump to search
| (134 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
| − | Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]]. | + | Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]]. |
| + | |||
| + | Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage. | ||
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles=== | ===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles=== | ||
| + | |||
| + | * [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]] | ||
| + | |||
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | * [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | ||
| + | :* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 Dec-2014]] | ||
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ||
| − | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease | + | |
| − | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist | + | *[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | 18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker 2018-06-20]] |
| − | * [[Media: | + | |
| − | + | *[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | MR Elastography of the Liver 2018-05-02]] | |
| + | |||
| + | * [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean.pdf|QIBA CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening]] ''2018.11.18'' | ||
| + | |||
| + | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]] | ||
| + | |||
| + | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | ||
| + | |||
| + | *[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]] | ||
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ||
| − | |||
| − | + | '''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']''' | |
| − | *[[Media: | + | |
| − | *[[Media: | + | *[[Media:QIBADWIProfile_as_of_2019-Feb-05.pdf|Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-02-05]] ('''closed''' on EOB April 5th) |
| + | |||
| + | *[[Media:QIBA_CTA_Profile_as_of_2019-Feb-29.pdf| Atherosclerosis Biomarkers by (C)CTA - 2019 Imaging Profile 2019-02-26]] (open for public comment until EOB June 3rd) | ||
| + | |||
| + | |||
| + | '''[[Comment Resolutions]]''' are posted for '''Past Public Comments''' and '''Past Technical Confirmations''' . | ||
| + | |||
| + | |||
| + | ==Format for Citing Profiles== | ||
| + | Cite QIBA Profile documents as: | ||
| − | ''' | + | : ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. QIBA, ''Date''. Available from: ''URL'' |
| − | |||
| − | |||
| + | Example: | ||
| − | + | : QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles | |
| − | |||
| − | |||
| − | : | ||
| − | |||
| − | |||
==Statements of Endorsement== | ==Statements of Endorsement== | ||
Revision as of 19:06, 14 May 2019
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
Please submit comments using the online form
- Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-02-05 (closed on EOB April 5th)
- Atherosclerosis Biomarkers by (C)CTA - 2019 Imaging Profile 2019-02-26 (open for public comment until EOB June 3rd)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations .
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. QIBA, Date. Available from: URL
Example:
- QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)